This growth can be attributed to factors such as emergence of biosimilars, increasing demand for mAbs, increasing adoption of target therapy over traditional therapy, high prevalence of cancer.
According to research report the Cancer Immunotherapy Market is projected to reach $119.39 Billion by 2021, at a CAGR of 14.0%.
The Lung Cancer segment is expected to grow at a high CAGR, owing to the increase in prevalence, patient pool urges a demand for advanced treatment options, and this increases the growth of Cancer Immunotherapy market. The current immunotherapies for lung cancer treatment, such as checkpoint inhibitors, monoclonal antibodies, therapeutic vaccines, and other cell therapies, have benefited some patients with advanced lung cancer in the form of durable remission and prolonged survival.
Antibodies are developed to treat several cancers such as lymphoma, leukemia, melanoma, breast cancer, and lung cancer. Cancer monoclonal antibodies are sub-segmented into naked monoclonal antibodies, conjugated monoclonal antibodies, and bispecific monoclonal antibodies. Monoclonal antibodies are emerging as the most effective therapeutic agents for the treatment of malignancy. They are currently one of the largest classes of agents approved for the treatment of cancer. Several antibodies are widely adopted, owing to their lesser side effects as compared to chemotherapy.
The major players in the cancer immunotherapy market are Amgen (U.S.), AstraZeneca (U.K.), F. Hoffman La-Roche (Switzerland), Bristol-Myers Squibb (U.S.), Eli Lilly and Company (U.S.), Janssen Global Services, LLC (Belgium), Bayer AG (Germany), Merck (U.S.), Novartis (Switzerland), and Pfizer (U.S.).
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=197577894